Edwards Lifesciences Corp. ( (EW) ) has released its Q1 earnings. Here is a breakdown of the information Edwards Lifesciences Corp. presented to its investors.
Edwards Lifesciences Corp. is a leading global company specializing in structural heart innovations, focusing on improving patient lives through advanced medical technologies. In its latest earnings report, Edwards Lifesciences announced a 6.2% increase in first-quarter sales, reaching $1.41 billion, with a notable 58% growth in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales. The company’s earnings per share (EPS) stood at $0.62, with an adjusted EPS of $0.64. Key highlights include the CE Mark approval for the SAPIEN M3, enhancing their TMTT portfolio, and the finalized NCD for transcatheter tricuspid valve replacement, which expands patient access to their EVOQUE system. Edwards Lifesciences reported strong performance in its Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, marking a 3.8% growth. The company continues to focus on expanding its differentiated technology and increasing therapy adoption globally. Additionally, the surgical segment saw a modest 1% increase in sales, driven by the premium RESILIA tissue portfolio. Looking ahead, Edwards Lifesciences is optimistic about its 2025 outlook, raising its TMTT sales guidance and maintaining its overall sales growth forecast. The company remains committed to driving innovation and expanding its market presence to transform care for structural heart patients worldwide.